ProCE Banner Activity

How I Use Immunotherapy to Treat Metastatic HER2-Negative Gastric Cancer

Clinical Thought

In this commentary, Steven Maron, MD, describes how he approaches immunotherapy for treating metastatic, HER2-negative gastric cancer, including a discussion of best practices in managing immune-related adverse events.

Released: November 29, 2022

Expiration: November 28, 2023

Share

Faculty

Steven Maron

Steven Maron, MD

Assistant Attending Physician
Gastrointestinal Medical Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Supporters

This activity is supported by

Bristol Myers Squibb

Additional Information

Program Medium

This program has been made available online.